NCT07778173Recruiting
Three-Dimensional Molds Based on Radiological imagEs in Patients With Cancer: the DIRECT Trial
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Determination of the sites from which the histopathological samples in surgically removed lesions are collected is still done by eye by a pathologist. As radiological determination of regions of interest has already proven useful in in vivo use cases, the implementation of sampling of ex vivo lesions with the help of radiological imaging suggests great potential. By developing and implementing mold printing processes, these molds have the potential to vastly improve the accuracy and consistency of histopathological sampling and collection of tissue samples from different regions of tumor, leading to improved characterization, more individualized treatments, and eventually better survival.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- 31 May 2024
- Primary completion date
- 31 Dec 2033
- Lead sponsor
- Tampere University Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT07778173
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 31 May 2024 to the primary completion date, 31 Dec 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- To be eligible for the study, the study candidate cannot:
- lack the capacity to provide informed consent (if a legal guardian objects to the participation of their child (\<15-year-old), the child is not eligible);
- be at risk of having their standard of care treatment jeopardized by the study, in the opinion of their physician.
Who the study is looking for
- To be eligible for the study, the study candidate must:
- be willing and able to give informed consent and give their written consent for the participation in the study (in case of a child (\<15-year-old), the consent is collected in an age-appropriate manner from the study candidate and their legal guardian(s))
- have a malignant or likely malignant tumor/tumors and undergo a surgical operation.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tampere University Hospital Coordinator of this site? Confirm its status | Tampere | Finland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.